Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    34.249,77
    +310,02 (+0,91%)
     

  • Dow Jones

    38.239,66
    +153,86 (+0,40%)
     

  • Nasdaq

    15.927,90
    +316,14 (+2,03%)
     

  • Nikkei 225

    37.934,76
    +306,28 (+0,81%)
     

  • Petrolio

    83,66
    +0,09 (+0,11%)
     

  • Bitcoin EUR

    59.103,26
    -770,97 (-1,29%)
     

  • CMC Crypto 200

    1.304,48
    -92,06 (-6,59%)
     

  • Oro

    2.349,60
    +7,10 (+0,30%)
     

  • EUR/USD

    1,0699
    -0,0034 (-0,32%)
     

  • S&P 500

    5.099,96
    +51,54 (+1,02%)
     

  • HANG SENG

    17.651,15
    +366,61 (+2,12%)
     

  • Euro Stoxx 50

    5.006,85
    +67,84 (+1,37%)
     

  • EUR/GBP

    0,8558
    -0,0015 (-0,18%)
     

  • EUR/CHF

    0,9770
    -0,0015 (-0,15%)
     

  • EUR/CAD

    1,4617
    -0,0032 (-0,22%)
     

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

KALA BIO, Inc.
·2 minuto per la lettura

ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded presentation will be made available beginning on Monday, September 11, 2023 at 7:00 a.m. ET. Management will also be available for one-on-one meetings throughout the conference.

To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.

About KALA BIO, Inc.

KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.

Investor Contact:

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200